Related Experiment Video
Updated: May 2, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Small molecule-facilitated degradation of ANO1 protein: a new targeting approach for anticancer therapeutics
Anke Bill1, Michelle Lynn Hall1, Jason Borawski1
1Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139.
Abstract:
ANO1, a calcium-activated chloride channel, is highly expressed and amplified in human cancers and is a critical survival factor in these cancers. The ANO1 inhibitor CaCCinh-A01 decreases proliferation of ANO1-amplified cell lines; however, the mechanism of action remains elusive. We explored the mechanism behind the inhibitory effect of CaCCinh-A01 on cell proliferation using a combined experimental and in silico approach. We show that inhibition of ANO1 function is not sufficient to diminish proliferation of ANO1-dependent cancer cells. We report that CaCCinh-A01 reduces ANO1 protein levels by facilitating endoplasmic reticulum-associated, proteasomal turnover of ANO1. Washout of CaCCinh-A01 rescued ANO1 protein levels and resumed cell proliferation. Proliferation of newly derived CaCCinh-A01-resistant cell pools was not affected by CaCCinh-A01 as compared with the parental cells. Consistently, CaCCinh-A01 failed to reduce ANO1 protein levels in these cells, whereas ANO1 currents were still inhibited by CaCCinh-A01, indicating that CaCCinh-A01 inhibits cell proliferation by reducing ANO1 protein levels. Furthermore, we employed in silico methods to elucidate novel biological functions of ANO1 inhibitors. Specifically, we derived a pharmacophore model to describe inhibitors capable of promoting ANO1 degradation and report new inhibitors of ANO1-dependent cell proliferation. In summary, our data demonstrate that inhibition of the channel activity of ANO1 is not sufficient to inhibit ANO1-dependent cell proliferation, indicating that the role of ANO1 in cancer only partially depends on its function as a channel. Our results provide an impetus for gaining a deeper understanding of ANO1 modulation in cells and introduce a new targeting approach for antitumor therapy in ANO1-amplified cancers.
Insights
The calcium-activated chloride channel ANO1 inhibitor CaCCinh-A01 reduces cancer cell proliferation by decreasing ANO1 protein levels, not just by inhibiting channel activity. This reveals a new therapeutic strategy for ANO1-amplified cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- ANO1 (Anion Exchanger 1) is a calcium-activated chloride channel highly expressed in human cancers.
- ANO1 amplification is linked to cancer cell survival, making it a potential therapeutic target.
- The exact mechanism by which ANO1 inhibitors affect cancer cell proliferation is not fully understood.
Purpose of the Study:
- To elucidate the mechanism of action of the ANO1 inhibitor CaCCinh-A01 on cancer cell proliferation.
- To investigate whether ANO1 channel inhibition or protein level reduction is responsible for the anti-proliferative effect.
- To identify novel ANO1 inhibitors and understand their pharmacophore for promoting ANO1 degradation.
Main Methods:
- Combined experimental (cell culture, protein level analysis) and in silico (pharmacophore modeling) approaches.
- Treatment of ANO1-amplified cancer cell lines with CaCCinh-A01.
- Analysis of ANO1 protein levels, channel activity, and cell proliferation.
- Development of CaCCinh-A01-resistant cell lines.
- In silico derivation of a pharmacophore model for ANO1 degradation-promoting inhibitors.
Main Results:
- Inhibition of ANO1 channel function alone was insufficient to decrease proliferation in ANO1-dependent cancer cells.
- CaCCinh-A01 significantly reduced ANO1 protein levels by promoting its endoplasmic reticulum-associated, proteasomal degradation.
- Washout of CaCCinh-A01 restored ANO1 protein levels and cell proliferation.
- CaCCinh-A01-resistant cells showed no proliferation defect and maintained higher ANO1 protein levels, despite continued channel inhibition.
- A pharmacophore model for ANO1 degradation enhancers was developed, identifying new potential inhibitors.
Conclusions:
- The anti-proliferative effect of CaCCinh-A01 on ANO1-amplified cancers is primarily mediated by the reduction of ANO1 protein levels, not solely by channel inhibition.
- ANO1's role in cancer survival is only partially dependent on its channel function, suggesting broader regulatory mechanisms.
- Targeting ANO1 protein degradation represents a novel therapeutic strategy for ANO1-amplified cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Drugs that Destabilize Microtubules
01:15Drugs that Stabilize Microtubules
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...